Drug Profile
Research programme: ADAM8 inhibitors - Cancer Research Technology/Medivir
Alternative Names: ADAM8 inhibitors - MedivirLatest Information Update: 24 Nov 2015
Price :
$50
*
At a glance
- Originator Kings College London
- Developer Cancer Research Technology; Kings College London; Medivir AB; TransMIT Gesellschaft fur Technologietransfer mbH
- Class Small molecules
- Mechanism of Action ADAM protein inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Pancreatic cancer